Correlates of HIV-1 control after combination immunotherapy. (PubMed, Nature) - Dec 2, 2025 - P1/2 | "We performed a single-arm, proof-of-concept study in ten people with HIV on ART combining the following three approaches: (1) therapeutic vaccination with an HIV/Gag conserved element (CE)-targeted DNA+IL-12 prime/MVA boost regimen followed by (2) administration of two bNAbs (10-1074, VRC07-523LS) and a toll-like receptor 9 agonist (lefitolimod) during ART suppression, followed by (3) repeat bNAb administration at the time of ART interruption (NCT04357821). Robust expansion of activated CD8+ T cells early in response to rebounding virus correlated with lower median viral load following peak viremia off ART. These data suggest that combination immunotherapy approaches might prove effective to induce sustained control of HIV by slowing rebound and improving CD8+ T cell responses, and that these approaches should continue to be optimized."
Journal • Human Immunodeficiency Virus • Infectious Disease • CD8 • IL12A
|
|
A N Deitchman; B K Felber; C J Petropoulos; D A Sandel; D SenGupta; D V Glidden; E Vendrame; G M Borgo; G N Pavlakis; H P Tummala; J D Reeves; J I Mullins; J Tisoncik-Go; K Schwartz; K W Chew; L B Cohn; L Gama; L S Whitmore; L Serebryannyy; L Zemelko; M C Nussenzweig; M C Williams; M Caskey; M Deswal; M Gale; M H Spitzer; M J Peluso; M Khalili; M Shimoda; R A Koup; R Hoh; R L Rutishauser; R Tibúrcio; S A Yukl; S G Deeks; S J Kim; S Narpala; S S Singh; T Dalhuisen; T J Henrich
|